UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 30, 2021

Avient Corporation

(Exact Name of Registrant as Specified in Its Charter)

Ohio

1-16091

34-1730488

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

Avient Center 33587 Walker Road Avon Lake, Ohio 44012

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (440) 930-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Shares, par value \$.01 per share	AVNT	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On April 30, 2021, the Registrant issued a press release, furnished herewith as Exhibit 99.1, announcing earnings for the first quarter of 2021. The press release shall not be deemed to be "filed" under the Securities Exchange Act of 1934.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Number</u>	<u>Exhibit</u>
<u>99.1</u>	Press release dated April 30, 2021.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVIENT CORPORATION

<u>By: /s/ Jamie A. Beggs</u> Name: Jamie A. Beggs Title: Senior Vice President and Chief Financial Officer

Dated: April 30, 2021



NEWS RELEASE

Avient Announces Record First Quarter 2021 Results; Increases Full Year Guidance

- Organic revenues increased 17% to \$1.16 billion driven by strong demand across all segments, with the most significant growth in healthcare and consumer end markets
- GAAP EPS from continuing operations of \$0.86 compared to \$0.38 in the prior year quarter
- Adjusted EPS from continuing operations of \$0.89 expanded 68% over the prior year of \$0.53 with all segments achieving record operating income
- Full year adjusted EPS guidance for 2021 increased from \$2.40 to \$2.80 representing 45% growth over the prior year of \$1.93.


CLEVELAND – April 30, 2021 – Avient Corporation (NYSE: AVNT), a leading provider of specialized and sustainable material solutions, today reported its first quarter results for 2021. First quarter 2021 GAAP EPS from continuing operations was \$0.86 compared to \$0.38 in the prior year first quarter. The company noted that GAAP EPS includes special items (Attachment 3), which impacted EPS in both periods and were primarily associated with acquisition-related and restructuring costs. Unless otherwise noted herein, all comparisons to prior year results are pro forma for the Clariant Masterbatch acquisition.

"I'm very pleased to report we achieved the highest level of organic sales growth in the last decade, as the economy recovers from the pandemic lows of the prior year. This is a direct result of the investments we have made to transform our portfolio to one that is more specialized and focused on high growth end markets with sustainable solutions," said Robert M. Patterson, Chairman, President and Chief Executive Officer, Avient Corporation.

The company cited strong demand for healthcare (up 22%) and consumer products (up 24%) as organic revenue increased 17% to \$1.16 billion. Coupled with expanding margins, and early synergy capture related to the Clariant Masterbatch acquisition, this led to a 68% increase in adjusted EPS to \$0.89 versus \$0.53 in the prior year.



Specialty EBITDA Margins



Mr. Patterson added, "We are an asset-light, high-touch business that generates very high free cash flow conversion. We specialize in formulating sustainable solutions to meet our customers' toughest challenges, and I am proud of how well our team has delivered throughout the COVID-19 pandemic and recent supply chain disruptions."

The company noted the following segment highlights:

The Color, Additives and Inks segment delivered record operating income of \$89 million during the first quarter, a 40% increase over the prior year. The company said it is ahead of schedule in capturing cost synergies from the Clariant Masterbatch acquisition and now expects to achieve \$45 million in the current year from the previously announced \$35 million.

The Specialty Engineered Materials segment also achieved its highest-ever quarterly operating income at \$34 million, a 53% increase over the prior year. Demand conditions were robust in the quarter, in particular for composite technologies and new business gains in healthcare applications.

Despite significant supply chain disruptions, the company's Distribution segment also performed exceptionally well to start the year, highlighted by record quarterly operating income of \$24 million, a 24% increase over the prior year, as sales increased 25% to \$363 million.

Second Quarter and Full Year 2021 Outlook

Commenting on the Company's 2021 outlook, Mr. Patterson said, "As more and more vaccines are administered, we anticipate demand conditions will continue to improve. We now estimate second quarter sales of \$1.1 billion and adjusted EPS of \$0.80. This represents sales and adjusted EPS growth of 26% and 90%, respectively, over the prior year second quarter."

Mr. Patterson added, "We are also increasing our full year 2021 estimates and now expect revenues of approximately \$4.3 billion and adjusted EPS of \$2.80, a 45% increase over the prior year."

"As companies report their earnings this year and compare to 2020, there will be many examples of significant growth being delivered. This is the case for Avient as well, but what further differentiates us, is that in 2020 our EPS also grew 11% vs. 2019. Our EPS projections for 2021 are 61% higher than 2019 because of the resiliency of our portfolio, the end markets we serve and how we have executed during these challenging times," Mr. Patterson concluded.



The Company noted it will provide more details on its 2021 outlook during the webcast scheduled for 9:00 a.m. Eastern Time on April 30, 2021.

Pro Forma

The Company acquired the Clariant Masterbatch business ("CMB") on July 1, 2020 (the "Acquisition Date"). Unless otherwise noted, all comparisons to prior year financial results herein are presented on a pro forma basis and referred to as "organic" such that the prior periods include the business results of CMB for that prior period. Management believes this provides better comparability of the performance of the combined businesses. Refer to Attachment 7 Reconciliation of Non-GAAP Financial Measures for details regarding adjustments to previously reported results to arrive to the pro forma financial metrics.

Webcast Details

The webcast can be viewed live at <u>avient.com/investors</u>, or by clicking here: <u>https://edge.media-server.com/mmc/p/eaivs28r</u>. To participate in the audio-only portion of the call, dial 1-844-835-7433 (domestic) or 1-914-495-8589 (international) and provide conference ID number 6746706. There will be a question and answer session following the company's presentation and prepared remarks.

A recording of the webcast and the slide presentation will be available at <u>avient.com/investors</u>. In addition, a recording of the audio will be available for one week, beginning at 12:00 p.m. ET on Friday, April 30, 2021. To access, dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and provide conference ID number 6746706.

About Avient

Avient Corporation (NYSE: AVNT), with 2020 pro forma revenues of \$3.8 billion, provides specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world. Examples include:

- Barrier technologies that preserve the shelf-life and quality of food, beverages, medicine and other perishable goods through high-performance materials that require less plastic
- Light-weighting solutions that replace heavier traditional materials like metal, glass and wood, which can improve fuel efficiency in all modes of transportation
- Breakthrough technologies that minimize wastewater and improve the recyclability of materials and packaging across a spectrum of end uses

Avient employs approximately 8,400 associates and is certified ACC Responsible Care®, a founding member of the Alliance to End Plastic Waste and certified Great Place to Work®. For more information, visit <u>www.avient.com</u>.

###

Forward-looking Statements

In this press release, statements that are not reported financial results or other historical information are "forwardlooking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events and are not guarantees of future performance. They are based on management's expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales. Factors that could cause actual results to differ materially from those implied by these forward-looking statements include disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; the current and potential future impact of the COVID-19 pandemic on our business, results of operations, financial position or cash flows: our ability to achieve the strategic and other objectives relating to the acquisition of Clariant's Masterbatch business, including any expected synergies; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve the anticipated financial benefit from initiatives related to acquisition and integration working capital reductions, cost reductions and employee productivity goals; our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; information systems failures and cyberattacks; our ability to consummate and successfully integrate acquisitions; and amounts for cash and noncash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions. The above list of factors is not exhaustive.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.

Non-GAAP Reconciliation

The Company does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for adjusted earnings per share, to the most comparable GAAP financial measures on a forward-looking basis because the Company is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of certain items, such as, but not limited to, restructuring costs, environmental remediation costs, acquisition related costs, and other non-routine costs. Each of such adjustments has not yet occurred, are out of the Company's control and/or cannot be reasonably predicted. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Investor Relations Contact:

Giuseppe (Joe) Di Salvo Vice President, Treasurer and Investor Relations Avient Corporation +1 440-930-1921 giuseppe.disalvo@avient.com

Media Contact: Kyle G. Rose Vice President, Corporate Communications Avient Corporation +1 440-930-3162 kyle.rose@avient.com

Avient Corporation Summary of Condensed Consolidated Statements of Income (Unaudited) (In millions, except per share data)

	Th	Three Months Ended March 31,			
		2021		2020	
Sales	\$	1,162.3	\$	711.5	
Operating Income		120.4		52.8	
Net income from continuing operations attributable to Avient shareholders		79.3		33.1	
Basic earnings per share from continuing operations attributable to Avient shareholders	\$	0.87	\$	0.38	
Diluted earnings per share from continuing operations attributable to Avient shareholders	\$	0.86	\$	0.38	

Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results. Senior management believes these measures are useful to investors because they allow for comparison to Avient's performance in prior periods without the effect of items that, by their nature, tend to obscure Avient's operating results due to the potential variability across periods based on timing, frequency and magnitude. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or solely as alternatives to, financial measures prepared in accordance with GAAP. Below is a reconciliation of these non-GAAP financial measures to their most directly comparable financial measures calculated and presented in accordance with GAAP. See *Attachment 3* for a definition and summary of special items.

	Three Months Ended March 31, 2021			Three Months Ended Marcl 31, 2020				
Reconciliation to Condensed Consolidated Statements of Income		\$		EPS		\$		EPS
Net income from continuing operations attributable to Avient shareholders	\$	79.3	\$	0.86	\$	33.1	\$	0.38
Special items, after tax (Attachment 3)		2.6		0.03		8.6		0.10
Adjusted net income / EPS - excluding special items	\$	81.9	\$	0.89	\$	41.7	\$	0.48

Avient Corporation Condensed Consolidated Statements of Income (Unaudited) (In millions, except per share data)

	Three Months Ended March 31,				
		2021		2020	
Sales	\$	1,162.3	\$	711.5	
Cost of sales		859.9		540.0	
Gross margin		302.4		171.5	
Selling and administrative expense		182.0		118.7	
Operating income		120.4		52.8	
Interest expense, net		(19.3)		(9.4)	
Other income, net		1.5		1.6	
Income from continuing operations before income taxes		102.6		45.0	
Income taxes		(22.9)		(11.9)	
Net income from continuing operations		79.7		33.1	
Loss from discontinued operations, net of income taxes				(0.3)	
Net income		79.7		32.8	
Net income attributable to noncontrolling interests		(0.4)		_	
Net income attributable to Avient common shareholders	\$	79.3	\$	32.8	
Earnings per share attributable to Avient common shareholders - Basic:					
Continuing operations	\$	0.87	\$	0.38	
Discontinued operations				_	
Total	\$	0.87	\$	0.38	
Earnings per share attributable to Avient common shareholders - Diluted:					
Continuing operations	\$	0.86	\$	0.38	
Discontinued operations					
Total	\$	0.86	\$	0.38	
Cash dividends declared per share of common stock	\$	0.2125	\$	0.2025	
Weighted-average shares used to compute earnings per common share:					
Basic		91.3		86.3	
Diluted		92.2		86.7	

Avient Corporation Summary of Special Items (Unaudited) (In millions, except per share data)

Special items ⁽¹⁾	Three Months Ended March 31,						
		2021		2020			
Cost of sales:							
Restructuring costs, including accelerated depreciation and amortization	\$	(1.8)	\$	_			
Environmental remediation costs		(0.5)		(0.4)			
Reimbursement of previously incurred environmental costs		4.5		0.2			
Impact on cost of sales		2.2		(0.2)			
Selling and administrative expense:							
Restructuring, legal and other		(1.3)		(1.8)			
Acquisition earn-out adjustments		_		(1.0)			
Acquisition related costs		(3.3)		(6.7)			
Impact on selling and administrative expense		(4.6)		(9.5)			
Impact on operating income		(2.4)		(9.7)			
Other income, net		—		0.1			
Impact on income from continuing operations before income taxes		(2.4)		(9.6)			
Income tax benefit on above special items		0.9		2.0			
Tax adjustments ⁽²⁾		(1.1)		(1.0)			
Impact of special items on net income from continuing operations attributable to Avient Shareholders	\$	(2.6)	\$	(8.6)			
Diluted earnings per common share impact	\$	(0.03)	\$	(0.10)			
Weighted average shares used to compute adjusted earnings per share:							
Diluted		92.2		86.7			

(1) Special items include charges related to specific strategic initiatives or financial restructuring such as: consolidation of operations; debt extinguishment costs; costs incurred directly in relation to acquisitions or divestitures; employee separation costs resulting from personnel reduction programs, plant realignment costs, executive separation agreements; asset impairments; settlement gains or losses and mark-to-market adjustments associated with actuarial gains and losses on pension and other post-retirement benefit plans; environmental remediation costs, fines, penalties and related insurance recoveries related to facilities no longer owned or closed in prior years; gains and losses on the divestiture of operating businesses, joint ventures and equity investments; gains and losses on facility or property sales or disposals; results of litigation, fines or penalties, where such litigation (or action relating to the fines or penalties) arose prior to the commencement of the performance period; one-time, non-recurring items; and the effect of changes in accounting principles or other such laws or provisions affecting reported results.

⁽²⁾ Tax adjustments include the net tax benefit/(expense) from one-time income tax items, the set-up or reversal of uncertain tax position reserves and deferred income tax valuation allowance adjustments.

Avient Corporation Condensed Consolidated Balance Sheets (In millions)

	(Unaudited) March 31, 2021	December 31, 2020
ASSETS			
Current assets:			
Cash and cash equivalents	\$	594.5 \$	649.5
Accounts receivable, net		642.2	516.6
Inventories, net		357.0	327.5
Other current assets		122.7	108.5
Total current assets		1,716.4	1,602.1
Property, net		675.5	694.9
Goodwill		1,281.9	1,308.1
Intangible assets, net		973.3	1,008.5
Operating lease assets, net		80.9	80.9
Other non-current assets		181.4	176.0
Total assets	\$	4,909.4 \$	s 4,870.5
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities:			
Short-term and current portion of long-term debt	\$	18.8 \$	5 18.6
Accounts payable		529.6	471.7
Current operating lease obligations		24.3	25.1
Accrued expenses and other current liabilities		290.9	285.6
Total current liabilities		863.6	801.0
Non-current liabilities:			
Long-term debt		1,852.7	1,854.0
Pension and other post-retirement benefits		111.3	115.0
Non-current operating lease obligations		56.8	56.0
Other non-current liabilities		303.0	332.8
Total non-current liabilities		2,323.8	2,357.8
SHAREHOLDERS' EQUITY			
Avient shareholders' equity		1,707.0	1,697.1
Noncontrolling interest		15.0	14.6
Total equity		1,722.0	1,711.7
Total liabilities and equity	\$	4,909.4 \$	4,870.5

Avient Corporation Condensed Consolidated Statements of Cash Flows (Unaudited) (In millions)

Vet income \$ 79.7 \$ 32 Adjustments to reconcile net income to net cash provided by operating activities: 36.6 19 Depreciation and amortization 36.6 19 Accelerated depreciation and amortization 0.5 - Share-based compensation expense 2.7 2 Changes in ascests and liabilities, net of the effect of acquisitions: (137.6) (56 Increase in accounts receivable (35.1) (13 Increase in accounts receivable (37.3) 44 Decrease in pension and other post-retirement benefits (7.1) (3 Increase in post-acquisition earnout liabilities, net (3.4) (19 Payment of post-acquisition date earnout liabilities, net (3.4) (19 Payment of post-acquisition date earnout liabilities - (21 Vet cash provided (used) by operating activities (16.5) (11 Start accounts payable - (20) 5 Vet cash quotide by other assets (20) 5 (12 Vet proceeds (used) provided hy investing activities (12.5) (11 <		Three Months Ended March 31,			
Vet income \$ 79.7 \$ 32 Adjustments to reconcile net income to net cash provided by operating activities: 36.6 19 Depreciation and amortization 36.6 19 Accelerated depreciation and amortization 0.5 - Share-based compensation expense 2.7 2 Changes in ascests and liabilities, net of the effect of acquisitions: (137.6) (56 Increase in accounts receivable (137.6) (56 Increase in accounts receivable (35.1) (13 Increase in pension and other post-retirement benefits (7.1) (3 Increase in post-acquisition earmout liabilities, net (3.4) (19 Payment of post-acquisition date aernout liabilities, net (3.4) (19 Payment of post-acquisition date aernout liabilities - (21 Vet cash provided (used) by operating activities (16.5) (11 Set cash (used) provided by other assets (20) 5 Vet cash (used) provided by other assets (2.0) 5 Vet cash (used) provided by other assets (2.3) (2 <td< th=""><th></th><th> 2021</th><th>2020</th></td<>		 2021	2020		
Adjustments to reconcile net income to net cash provided by operating activities: 36.6 19 Depreciation and amoritzation 0.5 Share-based compensation expense 2.7 2 Changes in assets and liabilities, net of the effect of acquisitions: (137.6) (56 Increase in accounts receivable (137.6) (56 Increase in inventories (35.1) (133 Increase in pension and other post-retirement benefits (7.1) (3 Increase in post-acquisition earnout liabilities, net (3.4) (19 Payment of post-acquisition date annout liabilities, net (3.4) (19 Payment of post-acquisition date earnout liabilities, net (3.4) (19 Payment of post-acquisition date earnout liabilities, net (3.6) (12 Vet cash provided (used) by operating activities (3.6) (12 Paytia expenditures (16.5) (11 Vet proceeds from divestiture - 7 Vet cash provided by investing activities (18.5) 1 Tinancing activities (2.0) 5 Vet cash (used) provided by investing activities (2.3) (2 Paytic	Operating Activities				
Depreciation and amortization36.619Accelerated depreciation and amortization0.5-Share-based compensation expense2.72Changes in assets and liabilities, net of the effect of acquisitions:(137.6)(56Increase in accounts receivable(35.1)(13)Increase in accounts payable67.344Decrease in opst-acquisition earnout liabilities, net(7.1)(3)Increase in account spayable(7.1)(3)Decrease in accound expenses and other assets and liabilities, net(3.4)(19)Payment of post-acquisition date earnout liabilities, net(3.4)(12)Payment of post-acquisition date earnout liabilities(16.5)(11)Vesting activities(16.5)(11)(16.5)(11)Vest proceeds from divestiture77Vet cash (used) provided by other assets(2.0)5(16.5)(11)Vet case of common shares for treasury(4.2)(13)(11)Varchase of common shares for treasury(4.2)(13)(12)Varchase of underwriting discount and issuance costs496Agament of long-term debt(2.3)(2)(2)Vet act (used) provided by financing activities(3.1)(11)Capit date garant is dislities, path discount and issuance costs496Agament of ong-term debt(2.3)(2)(2)Vet cash (used) provided by financing activities(2).14300Capit date garant isbility-	Net income	\$ 79.7 \$	32.8		
Accelerated depreciation and amortization0.5Share-based compensation expense2.72changes in assets and liabilities, net of the effect of acquisitions:(137.6)(56Increase in accounts receivable(137.6)(56Increase in accounts payable67.344Decrease in post-acquisition earnout liabilities-1Decrease in post-acquisition earnout liabilities, net(3.4)(19)Payment of post-acquisition date earnout liabilities, net(3.4)(19)Payment of post-acquisition date earnout liabilities, net3.6(12)vet cash provided (used) by operating activities3.6(12)Payment of post-acquisition date earnout liabilities, net(6.5)(11)Vet cash provided (used) by operating activities3.6(12)Payment of post-acquisition date earnout liability-7Vet proceeds (used) provided by other assets(2.0)5Vet proceeds (used) provided by other assets(2.0)5Vet cash (used) provided by other assets(2.0)5Vet cash (used) provided by investing activities(18.5)1Inacting activities(19.5)(15)(15)Payment of long-term debt(2.3)(22Payment of long-term debt(3.1)(1(1Payment of long-term debt(2.1)(40)(3)(2)Payment of long-term debt(2.3)(222Payment of long-term debt(3.1)(1(3)(1)Payment of lo	Adjustments to reconcile net income to net cash provided by operating activities:				
Share-based compensation expense 2.7 2 Changes in assets and liabilities, net of the effect of acquisitions: (137.6) (56 Increase in accounts receivable (35.1) (13 Increase in inventories (35.1) (13 Increase in post-acquisition earnout liabilities (7.1) (3 Increase in post-acquisition earnout liabilities - 1 Decrease in accrued expenses and other assets and liabilities, net (3.4) (19 Payment of post-acquisition date earnout liabilities, net (3.4) (19 Payment of post-acquisition date earnout liability - (21 vet cash provided (used) by operating activities 3.6 (12 Capital expenditures (16.5) (11 Vet proceeds from divestiture - 7 vet cash (used) provided by investing activities (18.5) 1 Financing activities (18.5) 1 Purchase of common shares for treasury (4.2) (13 Cash dividends paid (19.5) (15 Reapyment of long-term debt (2.3) (2	Depreciation and amortization	36.6	19.9		
Changes in assets and liabilities, net of the effect of acquisitions: (137.6) (56 Increase in accounts receivable (35.1) (13 Increase in inventories (35.1) (13 Increase in accounts payable 67.3 44 Decrease in pension and other post-retirement benefits (7.1) (3 Increase in accounts payable	Accelerated depreciation and amortization	0.5			
Increase in accounts receivable (137.6) (56 Increase in inventories (35.1) (13 Increase in accounts payable 67.3 44 Decrease in post-acquisition earnout liabilities - 1 Decrease in post-acquisition earnout liabilities, net (3.4) (19 Payment of post-acquisition date earnout liability - (21 Vet cash provided (used) by operating activities 3.6 (12 nvesting activities - 7 Capital expenditures (16.5) (11 Vet proceeds from divestiture - 7 Vet proceeds (used) provided by other assets (2.0) 5 Vet proceeds (used) provided by investing activities (18.5) 1 Financing activities (19.5) (15 Payment of long-term debt (2.3) (2 Payment of long-term debt (2.3) (2 Payment of acquisition date earnout liability - 486 Payment of long-term debt (2.3) (2 Payment of long-term debt (2.3) (2	Share-based compensation expense	2.7	2.1		
Increase in inventories(35.1)(13)Increase in accounts payable67.344Decrease in post-acquisition earnout liabilities(7.1)(3)Increase in post-acquisition earnout liabilities-1Decrease in accrued expenses and other assets and liabilities, net(3.4)(19)Payment of post-acquisition date earnout liability-(21)Vet cash provided (used) by operating activities3.6(12)nvesting activities3.6(12)Appenditures(16.5)(11)Vet proceeds from divestiture-7Vet proceeds (used) provided by other assets(2.0)5Vet cash (used) provided by investing activities(18.5)1Financing activities(18.5)1Purchase of common shares for treasury(4.2)(13)Capayment of indirector share awards(3.1)(11)Equity offering proceeds, net of underwriting discount and issuance costs-496Payment of acquisition date earnout liability-(32)(21)Payment of acquisition date earnout liability-(32)(21)Cayment of onythed by privated by the asset s(2.9)(3.1)(11)Equity offering proceeds, net of underwriting discount and issuance costs-496Payment of acquisition date earnout liability-(32)(22)Cash (used) provided by financing activities(29.1)430(34)Cash (used) provided by financing activities(29.1)(33)(21)<	Changes in assets and liabilities, net of the effect of acquisitions:				
Increase in accounts payable67.344Decrease in pension and other post-retirement benefits(7.1)(3Increase in post-acquisition earnout liabilities-1Decrease in accrued expenses and other assets and liabilities, net(3.4)(19)Payment of post-acquisition date earnout liability-(21)Vet cash provided (used) by operating activities3.6(12)nevesting activities3.6(12)Avet cash provided (used) by operating activities(16.5)(11)Vet proceeds from divestiture-7Vet proceeds (used) provided by other assets(2.0)5Vet cash (used) provided by investing activities(18.5)1Financing activities(18.5)1Sepayment of long-term debt(2.3)(2Payment of voltholding tax on share awards(3.1)(1)Equity offering proceeds, net of underwriting discount and issuance costs-496Payment of acquisition date earnout liability-(32)Vet cash (used) provided by financing activities(29.1)(33)Cash dividends paid(29.1)(33)(1)Equity offering proceeds, net of underwriting discount and issuance costs-496Payment of acquisition date earnout liability-(32)Vet cash (used) provided by financing activities(29.1)(33)Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Increase in accounts receivable	(137.6)	(56.9)		
Decrease in pension and other post-retirement benefits(7.1)(3Increase in post-acquisition earnout liabilities-1Decrease in accrued expenses and other assets and liabilities, net(3.4)(19Payment of post-acquisition date earnout liability-(21Vet cash provided (used) by operating activities3.6(12nvesting activities3.6(12nvesting activities(16.5)(11Vet cash provided by other assets(16.5)(11Vet proceeds from divestiture-7Vet proceeds (used) provided by other assets(2.0)5Vet cash (used) provided by investing activities(18.5)1Financing activities(18.5)1Purchase of common shares for treasury(4.2)(13Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2'ayment of vithholding tax on share awards(3.1)(1Equity offering proceeds, net of underwriting discount and issuance costs-496'ayment of acquisition date earnout liability-(32Vet cash (used) provided by financing activities(29.1)4300Cash adu (ash equivalents at beginning of year(55.0)415Cash and cash equivalents at beginning of year649.5864	Increase in inventories	(35.1)	(13.0)		
Increase in post-acquisition earnout liabilities	Increase in accounts payable	67.3	44.6		
Decrease in accrued expenses and other assets and liabilities, net(3.4)(19Payment of post-acquisition date earnout liability—(21Net cash provided (used) by operating activities3.6(12nvesting activities(16.5)(11Capital expenditures(16.5)(11Net proceeds from divestiture—7Net cash provided by other assets(2.0)5Vet cash (used) provided by other assets(2.0)5Vet cash (used) provided by investing activities(18.5)1Financing activities(18.5)1Purchase of common shares for treasury(4.2)(13Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2Payment of acquisition date earnout liability—496Payment of acquisition date earnout liability—496Cash dividends paid(29.1)430Cash dividends paid to capuisition date earnout liability—496Payment of acquisition date earnout liability—496Cash dividende provided by financing activities(29.1)430Cash dividende provided by financing activities(29.1)430Cash cash equivalents at beginning of year649.5864	Decrease in pension and other post-retirement benefits	(7.1)	(3.2)		
Payment of post-acquisition date earnout liability—(21Net cash provided (used) by operating activities3.6(12nvesting activities(16.5)(11Capital expenditures(16.5)(11Vet proceeds from divestiture—7Vet proceeds (used) provided by other assets(2.0)5Vet cash (used) provided by investing activities(18.5)1Financing activities(19.5)(13Purchase of common shares for treasury(4.2)(13Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2Payment of acquisition date earnout liability—496Payment of acquisition date earnout liability—(32Vet cash (used) provided by financing activities(29.1)(430)Cash dused provided by financing activities(29.1)(430)Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Increase in post-acquisition earnout liabilities	—	1.0		
Net cash provided (used) by operating activities3.6(12Investing activities(16.5)(11Capital expenditures(16.5)(11Net proceeds from divestiture-7Vet proceeds (used) provided by other assets(2.0)5Vet cash (used) provided by investing activities(18.5)1Financing activities(18.5)1Purchase of common shares for treasury(4.2)(13Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2Payments of withholding tax on share awards(3.1)(1Equity offering proceeds, net of underwriting discount and issuance costs-496Payment of acquisition date earnout liability-(32Vet cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Decrease in accrued expenses and other assets and liabilities, net	(3.4)	(19.1)		
nvesting activitiesCapital expenditures(16.5)Capital expenditures(16.5)Net proceeds from divestiture-Yet proceeds (used) provided by other assets(2.0)Vet cash (used) provided by investing activities(18.5)Financing activities(18.5)Purchase of common shares for treasury(4.2)Cash dividends paid(19.5)Repayment of long-term debt(2.3)Payments of withholding tax on share awards(3.1)Equity offering proceeds, net of underwriting discount and issuance costs-Payment of acquisition date earnout liability-Quet cash (used) provided by financing activities(29.1)Vet cash (used) provided by financing activities(11.0)Cash and cash equivalents at beginning of year649.5	Payment of post-acquisition date earnout liability	_	(21.0)		
Capital expenditures(16.5)(11Vet proceeds from divestiture—7Vet proceeds (used) provided by other assets(2.0)5Vet cash (used) provided by investing activities(18.5)1Financing activities(18.5)1Purchase of common shares for treasury(4.2)(13Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2Payments of withholding tax on share awards(3.1)(1Equity offering proceeds, net of underwriting discount and issuance costs—496Payment of acquisition date earnout liability—(32Vet cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Net cash provided (used) by operating activities	 3.6	(12.8)		
Vet proceeds from divestiture-7Vet proceeds (used) provided by other assets(2.0)5Vet cash (used) provided by investing activities(18.5)1Financing activities(4.2)(13Purchase of common shares for treasury(4.2)(13Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2Payments of withholding tax on share awards(3.1)(1Equity offering proceeds, net of underwriting discount and issuance costs-496Payment of acquisition date earnout liability-(32Vet cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Investing activities				
Net proceeds (used) provided by other assets(2.0)5Net cash (used) provided by investing activities(18.5)1Financing activities(18.5)1Purchase of common shares for treasury(4.2)(13Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2Payments of withholding tax on share awards(3.1)(1Equipy offering proceeds, net of underwriting discount and issuance costs—496Payment of acquisition date earnout liability—(32Net cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Capital expenditures	(16.5)	(11.1)		
Net cash (used) provided by investing activities(18.5)1Financing activities	Net proceeds from divestiture	_	7.1		
Financing activitiesPurchase of common shares for treasury(4.2)(13Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2Payments of withholding tax on share awards(3.1)(1Equity offering proceeds, net of underwriting discount and issuance costs-496Payment of acquisition date earnout liability-(32Vet cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Net proceeds (used) provided by other assets	(2.0)	5.2		
Purchase of common shares for treasury(4.2)(13Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2Payments of withholding tax on share awards(3.1)(1Equity offering proceeds, net of underwriting discount and issuance costs—496Payment of acquisition date earnout liability—(32Vet cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Net cash (used) provided by investing activities	(18.5)	1.2		
Cash dividends paid(19.5)(15Repayment of long-term debt(2.3)(2Payments of withholding tax on share awards(3.1)(1Equity offering proceeds, net of underwriting discount and issuance costs—496Payment of acquisition date earnout liability—(32Vet cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Financing activities				
Repayment of long-term debt(2.3)(2Payments of withholding tax on share awards(3.1)(1)Equity offering proceeds, net of underwriting discount and issuance costs—496Payment of acquisition date earnout liability—(32)Vet cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3)Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Purchase of common shares for treasury	(4.2)	(13.6)		
Deayments of withholding tax on share awards(3.1)(1.Equity offering proceeds, net of underwriting discount and issuance costs—496Deayment of acquisition date earnout liability—(3.2)Vet cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3.2)Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Cash dividends paid	(19.5)	(15.6)		
Equity offering proceeds, net of underwriting discount and issuance costs—496Payment of acquisition date earnout liability—(32Vet cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Repayment of long-term debt	(2.3)	(2.0)		
Payment of acquisition date earnout liability—(32Net cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Payments of withholding tax on share awards	(3.1)	(1.3)		
Net cash (used) provided by financing activities(29.1)430Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Equity offering proceeds, net of underwriting discount and issuance costs	_	496.3		
Effect of exchange rate changes on cash(11.0)(3.Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Payment of acquisition date earnout liability	—	(32.9)		
Effect of exchange rate changes on cash(11.0)(3Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Net cash (used) provided by financing activities	(29.1)	430.9		
Decrease) increase in cash and cash equivalents(55.0)415Cash and cash equivalents at beginning of year649.5864	Effect of exchange rate changes on cash	(11.0)	(3.8)		
Cash and cash equivalents at beginning of year 649.5 864	(Decrease) increase in cash and cash equivalents	(55.0)	415.5		
· · · · · · · · · · · · · · · · · · ·	Cash and cash equivalents at beginning of year		864.7		
	Cash and cash equivalents at end of period	\$ 594.5 \$	1,280.2		

Avient Corporation Business Segment Operations (Unaudited) (In millions)

Operating income and earnings before interest, taxes, depreciation and amortization (EBITDA) at the segment level does not include: special items as defined in *Attachment 3*; corporate general and administration costs that are not allocated to segments; intersegment sales and profit eliminations; sharebased compensation costs; and certain other items that are not included in the measure of segment profit and loss that is reported to and reviewed by the chief operating decision maker. These costs are included in Corporate and eliminations.

Sales: Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Sales Gross margin: Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Gross margin Selling and administrative expense:	\$	2021 609.3 216.5 362.7 (26.2) 1,162.3 197.5 64.7	\$	2020 256.5 185.3 289.5 (19.8) 711.5
Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Sales Gross margin: Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Gross margin	\$	216.5 362.7 (26.2) 1,162.3 197.5	\$	185.3 289.5 (19.8)
Specialty Engineered Materials Distribution Corporate and eliminations Sales Gross margin: Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Gross margin	\$	216.5 362.7 (26.2) 1,162.3 197.5	\$	185.3 289.5 (19.8)
Distribution Corporate and eliminations Sales Gross margin: Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Gross margin		362.7 (26.2) 1,162.3 197.5		289.5 (19.8)
Corporate and eliminations Sales Gross margin: Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Gross margin		(26.2) 1,162.3 197.5		(19.8)
Sales Gross margin: Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Gross margin		1,162.3		. ,
Gross margin: Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Gross margin		197.5		711.5
Color, Additives and Inks Specialty Engineered Materials Distribution Corporate and eliminations Gross margin	\$			
Specialty Engineered Materials Distribution Corporate and eliminations Gross margin	\$			
Distribution Corporate and eliminations Gross margin		64.7	\$	89.4
Corporate and eliminations Gross margin		04.7		52.6
Gross margin		39.3		33.6
		0.9		(4.1)
Selling and administrative expense:	\$	302.4	\$	171.5
Color, Additives and Inks	\$	108.7	\$	48.9
Specialty Engineered Materials	•	30.5	Ŧ	30.3
Distribution		15.3		14.2
Corporate and eliminations		27.5		25.3
Selling and administrative expense	\$	182.0	\$	118.7
Operating income:				
Color, Additives and Inks	\$	88.8	\$	40.5
Specialty Engineered Materials		34.2		22.3
Distribution		24.0		19.4
Corporate and eliminations		(26.6)		(29.4)
Operating income	\$	120.4	\$	52.8
Earnings before interest, taxes, depreciation and amortization (EBITDA):				
Color, Additives and Inks	\$	116.2	\$	51.4
Specialty Engineered Materials	Ψ	42.0	Ψ	29.8
Distribution		24.2		19.5
Corporate and eliminations		(24.9)		(28.0)
Other income, net		1.5		1.6
EBITDA	\$	159.0	\$	74.3

Avient Corporation Reconciliation of Non-GAAP Financial Measures (Unaudited) (In millions, except per share data)

Senior management uses gross margin before special items and operating income before special items to assess performance and allocate resources because senior management believes that these measures are useful in understanding current profitability levels and how it may serve as a basis for future performance. In addition, operating income before the effect of special items is a component of Avient annual and long-term employee incentive plans and is used in debt covenant computations. Senior management believes these measures are useful to investors because they allow for comparison to Avient's performance in prior periods without the effect of items that, by their nature, tend to obscure Avient's operating results due to the potential variability across periods based on timing, frequency and magnitude. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or solely as alternatives to, financial measures prepared in accordance with GAAP. Below is a reconciliation of these non-GAAP financial measures to their most directly comparable financial measures calculated and presented in accordance with GAAP. See Attachment 3 for a definition and summary of special items.

	Three Months Ended March 31,							
Reconciliation to Consolidated Statements of Income	 2021		2020					
Sales	\$ 1,162.3	\$	711.5					
Gross margin - GAAP	302.4		171.5					
Special items in gross margin (Attachment 3)	(2.2)		0.2					
Adjusted Gross margin	\$ 300.2	\$	171.7					
Adjusted Gross margin as a percent of sales	25.8 %		24.1 %					
Operating income - GAAP	120.4		52.8					
Special items in operating income (Attachment 3)	2.4		9.7					
Adjusted Operating income	\$ 122.8	\$	62.5					
Adjusted Operating income as a percent of sales	10.6 %		8.8 %					

The table below reconciles pre-special income tax expense and the pre-special effective tax rate to their most comparable US GAAP figures.

			Three Moi Mare				
		2021			2020		
	GAAP Results	pecial tems	Adjusted Results	GAAP Results	Special Items	_	Adjusted Results
Income from continuing operations before income taxes	\$ 102.6	\$ 2.4	\$ 105.0	\$ 45.0	\$ 9.6	\$	54.6
Income tax expense - GAAP	(22.9)	_	(22.9)	(11.9)			(11.9)
Income tax impact of special items (Attachment 3)	_	(0.9)	(0.9)	_	(2.0)		(2.0)
Tax adjustments (Attachment 3)	—	1.1	1.1	—	1.0		1.0
Income tax (expense) benefit	\$ (22.9)	\$ 0.2	\$ (22.7)	\$ (11.9)	\$ (1.0)	\$	(12.9)
Effective Tax Rate ⁽¹⁾	22.3 %		21.6 %	26.5 %			23.7 %

⁽¹⁾ Rates may not recalculate from figures presented herein due to rounding

The following pro forma adjustments are referenced by management to provide comparable business performance by incorporating the Clariant Masterbatch business in periods prior to the acquisition date (July 1, 2020). Financial information referenced here is provided to aid in reconciling back to the most comparable GAAP figures.

Reconciliation of Pro Forma Adjusted Earnings per Share:	Three Months Ended March 3 2020				
Net income from continuing operations attributable to Avient shareholders	\$	33.1			
Special items, after tax (Attachment 3)		8.6			
Adjusted net income from continuing operations excluding special items		41.7			
Clariant MB pro forma adjustments to net income from continuing operations ⁽²⁾		7.8			
Pro forma adjusted net income from continuing operations attributable to Avient shareholders	\$	49.5			
Weighted average diluted shares		86.7			
Pro forma impact to diluted shares from January 2020 equity offering		6.1			
Pro forma weighted average diluted shares		92.8			
Adjusted EPS - excluding special items pro forma for Clariant MB acquisition	\$	0.53			

					De	Year Ended ecember 31, 20)20	1	
Reconciliation of Pro Forma Adjusted Earnings per Share:		Avient	Sp	ecial Items		Adjusted Avient		Clariant MB Pro Forma Adjustments ⁽²⁾	 Pro Forma Adjusted Avient
Sales	\$	3,242.1	\$	—	\$	3,242.1	\$	540.4	\$ 3,782.5
Operating income Interest expense, net	\$	189.3 (74.6)	\$	73.7 10.1	\$	263.0 (64.5)	\$	45.0 (18.1)	\$ 308.0 (82.6)
Other income, net		24.3		(17.6)		(04.3)		(10.1)	(02.0) 6.7
Income taxes		(5.2)		(41.4)		(46.6)		(6.2)	(52.8)
Net income attributable to noncontrolling interests		(1.8)				(1.8)		—	(1.8)
Net income from continuing operations attributable to Avient shareholders	\$	132.0	\$	24.8	\$	156.8	\$	20.7	\$ 177.5
Weighted average diluted shares Impact to diluted shares from January 2020 equity o Pro forma weighted average diluted shares	ffering								 90.6 1.5 92.1
Pro forma adjusted EPS									\$ 1.93

⁽²⁾ Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects to the financing for the acquisition

					De	Year Ended ecember 31, 20)19			
Reconciliation of Pro Forma Adjusted Earnings per Share:		Avient	Sp	oecial Items		Adjusted Avient		Clariant MB Pro Forma Adjustments ⁽³⁾	-	Pro Forma Adjusted Avient
Sales	\$	2,862.7	\$	_	\$	2,862.7	\$	1,118.6	\$	3,981.3
Operating income	\$	156.8	\$	71.7	\$	228.5	\$	72.9	\$	301.4
Interest expense, net		(59.5)		_		(59.5)		(33.4)		(92.9)
Other income, net		12.1		(10.0)		2.1		_		2.1
Income taxes		(33.7)		(5.9)		(39.6)		(9.1)		(48.7)
Net income attributable to noncontrolling interests		(0.2)		—		(0.2)		—		(0.2)
Net income from continuing operations attributable to Avient shareholders	\$	75.5	\$	55.8	\$	131.3	\$	30.4	\$	161.7
Weighted average diluted shares										77.7
Impact to diluted shares from January 2020 equity of	ffering	I								15.3
Pro forma weighted average diluted shares										93.0
Pro forma adjusted EPS									\$	1.74

⁽³⁾ Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects to the financing for the acquisition

Reconciliation of EBITDA by Segment	nciliation of EBITDA by Segment Three Months Ended March 31,					Ye	ar Enc	Ended December 31,				
		2021		2020	2020			2019		2018		
Operating income:									_			
Color, Additives and Inks	\$	88.8	\$	40.5	\$	180.8	\$	147.4	\$	158.5		
Specialty Engineered Materials		34.2		22.3		94.4		83.7		72.3		
Distribution		24.0		19.4		69.5		75.4		71.5		
Corporate and eliminations		(26.6)		(29.4)		(155.4)		(149.7)		(123.7)		
Operating income	\$	120.4	\$	52.8	\$	189.3	\$	156.8	\$	178.6		
Items below OI in Corporate:												
Other income, net	\$	1.5	\$	1.6	\$	24.3	\$	12.1	\$	(12.9)		
Depreciation & amortization:												
Color, Additives and Inks	\$	27.4	\$	10.9	\$	75.1	\$	42.7	\$	44.3		
Specialty Engineered Materials	Ŷ	7.8	Ŧ	7.5	Ŷ	30.0	Ŧ	29.5	Ŧ	23.2		
Distribution		0.2		0.1		0.7		0.5		0.7		
Corporate and eliminations		1.7		1.4		9.2		5.4		4.4		
Depreciation & Amortization	\$	37.1	\$	19.9	\$	115.0	\$	78.1	\$	72.6		
EBITDA: Color, Additives and Inks	\$	116.2	\$	51.4	\$	255.9	\$	190.1	\$	202.8		
Specialty Engineered Materials	φ	42.0	Φ	29.8	Φ	235.9 124.4	Φ	190.1	Φ	95.5		
Distribution		42.0 24.2		29.8 19.5		70.2		75.9		72.2		
Corporate and eliminations		(24.9)		(28.0)		(146.2)		(144.3)		(119.3)		
EBITDA	\$	159.0	\$	74.3	\$	328.6	\$	247.0	\$	238.3		
EBIIDA	Ψ	155.0	Ψ	74.5	Ψ	520.0	Ψ	247.0	Ψ	230.5		
EBITDA as a % of Sales:												
Color, Additives and Inks		19.1 %)	20.0 %		17.0 %)	18.9 %)	19.4 %		
Specialty Engineered Materials		19.4 %)	16.1 %		17.6 %		15.2 %)	14.8 %		
Distribution		6.7 %)	6.7 %		6.3 %)	6.4 %)	5.7 %		

Reconciliation of Pro Forma EBITDA - Color, Additives and Inks	Three Mont	ths Ended March 31,		 r Ended ember 31,		
	2020 2020		2019	2018		
Sales:						
Color, Additives and Inks	\$	256.5	\$ 1,502.9	\$ 1,003.8	\$	1,046.5
Clariant MB pro forma adjustments ⁽⁴⁾		279.4	 540.4	1,118.6		1,209.8
Pro forma sales	\$	535.9	\$ 2,043.3	\$ 2,122.4	\$	2,256.3
Operating income:						
Color, Additives and Inks	\$	40.5	\$ 180.8	\$ 147.4	\$	158.5
Clariant MB pro forma adjustments ⁽⁴⁾		23.0	45.0	72.9		80.3
Pro forma operating income	\$	63.5	\$ 225.8	\$ 220.3	\$	238.8
Depreciation & amortization:						
Color, Additives and Inks	\$	10.9	\$ 75.1	\$ 42.7	\$	44.3
Clariant MB pro forma adjustments ⁽⁴⁾		15.1	30.1	60.3		61.2
Pro forma depreciation & amortization	\$	26.0	\$ 105.2	\$ 103.0	\$	105.5
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA):						
Color, Additives and Inks	\$	51.4	\$ 255.9	\$ 190.1	\$	202.8
Clariant MB pro forma adjustments ⁽⁴⁾		38.1	 75.1	 133.2		141.5
Pro forma EBITDA	\$	89.5	\$ 331.0	\$ 323.3	\$	344.3
Pro forma EBITDA as a % of Sales		16.7 %	16.2 %	15.2 %)	15.3 %

	Three Months Ended March 31,				Year Ended December 31,				
Reconciliation to Adjusted EBITDA:		2021		2020	 2020		2019		2018
Net income from continuing operations – GAAP	\$	79.7	\$	33.1	\$ 133.8	\$	75.7	\$	87.4
Income tax expense		22.9		11.9	5.2		33.7		14.4
Interest expense		19.3		9.4	74.6		59.5		62.8
Debt extinguishment cost					—		—		1.1
Depreciation and amortization from continuing operations		37.1		19.9	115.0		78.1		72.6
EBITDA	\$	159.0	\$	74.3	\$ 328.6	\$	247.0	\$	238.3
Special items, before tax		2.4		9.6	66.2		61.7		59.5
Interest expense included in special items					(10.1)		—		_
Accelerated depreciation included in special items		(0.5)			(3.2)				(3.0)
Adjusted EBITDA	\$	160.9	\$	83.9	\$ 381.6	\$	308.7	\$	294.8

Reconciliation of Pro Forma Sales:	Three Month	s Ended March 31, 2020
Sales	\$	711.5
Clariant MB pro forma adjustment to sales ⁽⁴⁾		279.4
Pro forma sales	\$	990.9

 $^{\rm (4)}$ Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020)